The Roche group has stopped a Phase 3 trial of dalcetrapib, a novel treatment for patients with dyslipidemia due to the lack of clinically meaningful efficacy. The decision was taken on the recommendation of the data and safety monitoring board. ---Subscribe to MedNous to access this article--- Company News Research & University News